- Stephens started coverage on Akoya Biosciences Inc (NASDAQ:AKYA) with an Overweight rating and price target of $16.
- The analyst views Akoya as a leader in the rapidly advancing $14 billion spatial biology market.
- Relative to other players, the company has an established foothold in the spatial market with the largest installation base of around 800 instruments worldwide, the analyst writes.
- With upcoming competition, Stephens believes the value proposition of Akoya’s platforms and ability to provide end-to-end solutions will drive outsized market share gains as spatial phenotyping becomes the standard for tissue sample analysis.
- Additionally, through its partnerships, Akoya is further validating its platforms’ capabilities and generating the required evidence to access the $7 billion clinical market opportunity.
- In the most recent quarter, the company generated sales of $17.9 million, up 37% Y/Y, and raised FY22 sales guidance to $71-74 million from $70-73 million.
- Price Action: AKYA shares are up 1.14% at $12.82 on the last check Thursday.
Urban One, Inc. Receives NASDAQ Notification Of Non-Compliance With Listing Rule 5250(c)(1)
Today, Urban One, Inc. (NASDAQ:UONEK, UONE)))) (the "Company"), reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("NASDAQ") on August 16, 2023 (the "Third
